[{"orgOrder":0,"company":"Priothera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Priothera Receives FDA clearance of Investigational New Drug (IND) to start Phase 2b\/3 study with mocravimod in Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Priothera"},{"orgOrder":0,"company":"Priothera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Priothera Announces First Patients Enrolled in Pivotal MO-TRANS gLobal Phase 2b\/3 Study with Mocravimod as An Adjunctive and Maintenance Therapy for Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Priothera"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Bionical Emas","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bionical Emas Launches Expanded Access Program for JZP458 - A Recombinant Erwinia Asparaginase","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"IRELAND","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Jazz Pharmaceuticals"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
KRP203 (mocravimod) is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. This drug is in Phase 1 and Phase 2 trials for safety and tolerability, as well as for efficacy in several autoimmune indications such as AML patients undergoing HCT.
Global Phase 2b/3 trial (MO-TRANS) assessing the efficacy and safety of mocravimod, a novel S1P receptor modulator, as an adjunctive and maintenance therapy in AML patients undergoing allogeneic HSCT, planned to start in H2 2022.
JZP458 is launched for the treatment of adult and pediatric patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) following hypersensitivity or silent inactivation to E. coli-derived asparaginases.
Lead Product(s):
Recombinant Asparaginase Erwinia chrysanthemi